M&A Deal Summary

Ampersand Capital Partners Acquires Specac

On March 13, 2024, growth capital firm Ampersand Capital Partners acquired manufacturer Specac from Foresight Private Equity

Acquisition Highlights
  • This is Ampersand Capital Partners’ 2nd transaction in the Manufacturing sector.
  • This is Ampersand Capital Partners’ 2nd transaction in the United Kingdom.

M&A Deal Summary
Date 2024-03-13
Target Specac
Sector Manufacturing
Buyer(s) Ampersand Capital Partners
Sellers(s) Foresight Private Equity
Deal Type Secondary Buyout

Target

Specac

Orpington, United Kingdom
website
Specac is a manufacturer of high specification sample analysis and sample preparation equipment used in testing and research laboratories worldwide across a broad range of applications and end markets. Specac’s products are primarily focused on supporting IR Spectroscopy, an important analytical technique prevalent in both research and commercial-industrial labs. Specac was founded in 1971 and is based in Orpington, England.

Search 193,711 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Ampersand Capital Partners

Wellesley, Massachusetts, United States

Investor Investor Investor Investor Investor

website

Category Growth Capital Firm
Founded 1988
PE ASSETS 2.0B USD
Size Large
Type Sector Focused
DESCRIPTION

Ampersand Capital Partners is a middle-market private equity group that concentrates on growth equity investment opportunities in the healthcare sector. The Firm looks to invest $10 to $100 million in businesses with $10 to $100 million of revenue. Specific areas of interests within healthcare include lab products, specialty diagnostic equipment, pharmaceutical outsourcing, and specialty pharma. Ampersand generally prefers to be the first and sole institutional investor. Ampersand was formed in 1988 and is based in Wellesley, Massachusetts.

DEAL STATS #
Overall 78 of 79
Sector (Manufacturing) 2 of 2
Type (Secondary Buyout) 4 of 5
Country (United Kingdom) 2 of 2
Year (2024) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2023-11-28 Julius Clinical Research

Zeist, Netherlands

Julius Clinical Research is a scientifically focused CRO providing end-to-end clinical trial service to pharmaceutical and biotechnology customers, governments, and academia. The company combines operational excellence and a global network of research sites to deliver tailor-made solutions for customers and their clinical trials. Julius Clinical Research was formed in 2008 and is based in Zeist, Netherlands.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2024-03-19 Biologos

Montgomery, Illinois, United States

Biologos is a provider of sterile-filtered biological products (sera, reagents, buffers, cell culture media and other liquid solutions), primarily for veterinary pharmaceutical and organ transplant applications. Biologos was founded in 1976 and is based in Montgomery, Illinois.

Buy -

Seller(S) 1

SELLER

Foresight Private Equity

Investor Investor Investor Investor Investor

website

Category Private Equity Firm
Founded 1984
PE ASSETS 600M GBP
Size Middle-Market
Type Sector Agnostic
DESCRIPTION

Foresight Group LLP (Formerly VCF Partners)

DEAL STATS #
Overall 41 of 41
Sector (Manufacturing) 3 of 3
Type (Secondary Buyout) 9 of 9
Country (United Kingdom) 39 of 39
Year (2024) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2023-07-05 KSL Clinic

Kent, United Kingdom

KSL Clinic delivers FUE hair transplant treatments by offering complete hair restoration, for men and women of all ages suffering from baldness/hair loss. KSL Clinic is based in Kent.

Buy -
Mergr

Product

Company

Legal